 - Patients should not have received prior systemic chemotherapy for metastatic disease prior epidermal growth factor receptor EGFR, anaplastic lymphoma kinase ALK, kinase inhibitor therapy is allowed; prior adjuvant or neoadjuvant therapy for early stage disease is allowed if received 12 months prior to study entry 